Granisetron Transdermal Patch and Lumefantrine: Interaction Details
- Granisetron Transdermal Patch
- SancusoSustolGranisol
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Granisetron Transdermal Patch and Lumefantrine interaction:
Lumefantrine
We don't have a separate drug information page for Lumefantrine. The FDA's drug directory lists it as part of Coartem (artemether and lumefantrine). Read the Artemether and Lumefantrine drug information page → Have a question about Lumefantrine? Ask a pharmacist, free →
Granisetron Transdermal Patch
- Sancuso
- Sustol
- Granisol
What Happens When You Take Granisetron Transdermal Patch With Lumefantrine
What can happen when they are taken together (rated Major)
An increased risk of
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Artemether/lumefantrine should not be given together with agents that prolong the , since the combination may lead to QT prolongation. When using artemether/lumefantrine with a QT-prolonging agent is medically necessary, monitoring should be performed. Caution is also warranted when a QT-prolonging drug is started after artemether/lumefantrine treatment has ended, because lumefantrine has a long (3 to 6 days).1
The Granisetron Transdermal Patch and Lumefantrine Interaction, Explained
Lumefantrine (part of the malaria medicine artemether/lumefantrine) and the granisetron patch (Sancuso, used to prevent nausea from chemotherapy) can each affect your heart's electrical rhythm. Taken together, they may add up and raise the chance of a rhythm problem called . Signs can include dizziness, fainting, or a racing or fluttering heartbeat.
This is a theoretical concern based on how the drugs work, not on many reported cases. Lumefantrine also stays in your body for several days, so the overlap can last after your malaria treatment ends. Please don't stop or change anything on your own. Tell your pharmacist or doctor about both medicines so they can decide the safest plan, which may include a heart tracing ().
() between lumefantrine (artemether/lumefantrine) and granisetron (5-HT3 , transdermal). Neither drug's exposure is expected to change; the concern is combined effect on cardiac repolarization. Evidence: theoretical. Severity on file: major. Onset unspecified.
- Avoid when possible.
- If medically required, monitor (consider baseline ) and correct and .
- Lumefantrine is 3 to 6 days, so caution persists after the course is completed, including with a granisetron patch that is still in place or applied afterward.
- Consider non-QT-prolonging antiemetic alternatives where appropriate.
See the 1 reference behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Granisetron Transdermal Patch and Lumefantrine Interact
The likely mechanism
How to Manage the Granisetron Transdermal Patch and Lumefantrine Interaction
Your care team may avoid using these together. If both are truly needed, they may monitor you more closely, including an to check your heart rhythm.
- Keep taking both medicines as prescribed unless your prescriber tells you otherwise.
- Tell your pharmacist or prescriber about both drugs, especially if a patch is started after malaria treatment, since lumefantrine lingers for days.
- Mention any other medicines that affect heart rhythm.
- Report fainting, dizziness, or a pounding or irregular heartbeat right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Granisetron Transdermal Patch or Lumefantrine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Granisetron Transdermal Patch and Lumefantrine: Common Questions
How serious is the Granisetron Transdermal Patch and Lumefantrine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Granisetron Transdermal Patch and Lumefantrine interaction managed?
Your care team may avoid using these together. If both are truly needed, they may monitor you more closely, including an to check your heart rhythm. Keep taking both medicines as prescribed unless your prescriber tells you otherwise. Tell your pharmacist or prescriber about both drugs, especially if a patch is started after malaria treatment, since lumefantrine lingers for days. Mention any ot… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
Ask About the Granisetron Transdermal Patch and Lumefantrine Interaction
Ask in your own words about taking Granisetron Transdermal Patch and Lumefantrine together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (1)
- Product Information: COARTEM® oral tablets, artemether lumefantrine oral tablets. Novartis Pharmaceuticals Corporation (per DailyMed), East Hanover, NJ, 2025. DailyMed
Other Serious Interactions of Granisetron Transdermal Patch and Lumefantrine
Also serious with Lumefantrine
- CarbamazepineContraindicated
- DronedaroneContraindicated
- FluconazoleContraindicated
- Fluconazole InjectionContraindicated
Also serious with Granisetron Transdermal Patch
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.